Syn-Coll

Skincare

Also known as: Palmitoyl Tripeptide-5, Pal-Lys-Val-Lys, DSM Collagen Stimulator

Emerging Research

What is Syn-Coll?

A palmitoylated tripeptide developed by DSM (now dsm-firmenich) under the trademark Syn-Coll. Designed to stimulate collagen synthesis via the TGF-β signaling pathway, offering a mechanistic complement to Matrixyl-type peptides that work through extracellular matrix fragment mimicry.

How it works

Pal-Lys-Val-Lys mimics the collagen-stimulating activity of TGF-β1 by binding to the same receptor domain, activating downstream SMAD signaling and upregulating Type I collagen synthesis in dermal fibroblasts. The palmitic acid chain improves skin penetration. Different mechanism from Matrixyl (Pal-KTTKS), which mimics ECM fragments to trigger a wound-repair response — making Syn-Coll a potential complement in formulations targeting multiple collagen pathways.

What marketers claim

  • superior to retinol for collagen production
  • fills deep wrinkles in days
  • replaces TGF-β therapy

What evidence supports

  • in vitro: Pal-Lys-Val-Lys significantly increases Type I collagen expression in human fibroblast cultures
  • manufacturer-sponsored in vivo study: improved skin firmness and wrinkle depth reduction after 84 days at 3% concentration
  • mechanism via TGF-β1 pathway is pharmacologically plausible and supported by cell culture data

Research evidence

Key studies on Syn-Coll, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.

Palmitoyl tripeptide-5 stimulates collagen I via TGF-β pathway

2009In Vitro Study

Finding: Pal-Lys-Val-Lys at 1 ppm significantly upregulated Type I procollagen mRNA and protein in human fibroblasts; effect blocked by a TGF-β receptor antagonist confirming pathway specificity.

Limitation: In vitro, manufacturer-sponsored, penetration barriers in intact skin not accounted for.

Best for

fine linesaging skincollagen stimulationanti-aging preventionanti-aging skincare

What to expect

Realistic timeline based on available research. Individual results vary.

Week 1–4

No visible change; collagen synthesis increases in fibroblasts but remodeling takes time.

Week 8–12

Manufacturer data shows measurable improvements in skin firmness and wrinkle depth at 84 days.

Month 4+

Continued collagen accumulation; benefits are gradual and cumulative.

Safety notes & concerns

Full safety guide →
  • clinical evidence primarily manufacturer-sponsored (DSM) with limited independent trials
  • effective concentration in finished products rarely disclosed
  • collagen stimulation benefits require 8–12 weeks minimum — as with all signal peptides
  • TGF-β pathway activation has theoretical concerns with long-term overuse in some contexts

Pairs well with

Use caution with

generally well-tolerated; no established contraindications

Frequently asked questions

Is Syn-Coll better than Matrixyl?

They work through different pathways — Matrixyl mimics ECM fragments for wound-repair collagen synthesis; Syn-Coll directly activates TGF-β signaling in fibroblasts. Neither has clearly superior evidence in head-to-head trials. Many formulators combine them for a multi-pathway approach.

Related skincare peptides

🧪

Take the Peptide Quiz

Get personalized recommendations

🔬

Stack Builder

Build a routine with Syn-Coll

Last updated: 2026-06-10

Medical Disclaimer

The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.